Studies have shown that the drug Zytiga capable of increasing the life expectancy of patients with prostate cancer at the final stage, an average of four months. The drug was developed by British scientists specifically to help patients with aggressive forms of prostate tumors that do not respond to chemotherapy or other medicines.
Zytiga It works by overlapping receipt main "fuel" for the tumor - the hormone testosterone. Not receiving this hormone, the tumor stops growing. Clinical studies on nearly 800 patients in 13 countries have shown that taking Zytiga combined with modern steroid therapy patients lived 15 months, while patients on regular medication, only 11.
Research has proved so successful that they had to stop to immediately transfer all taking part in them patients Zytiga . Doctors noted that the drug improves the quality of life of patients. "Men with metastatic prostate cancer are, unfortunately, not a lot of treatment options, so they desperately need new drugs," - said in this regard, Professor Joan de Bono from the Institute of Cancer Research, which developed and Zytiga.
In the UK, 250,000 men currently living with prostate cancer, and every year doctors diagnose 37,000 cases. By the number of prostate cancer deaths are the second from cancer after lung cancer. Each year in the country dies 10 thousand people with prostate cancer.
Industry News
Go back to the main page
No comments:
Post a Comment